Oruka Therapeutics ORKA 深 沪
等待开盘 10-06 09:30:00 美东时间
84.38
-0.140
-0.17%
华盛通- 最 高107.225
- 今 开84.52
- 成交量 61.79万股
- 最 低 81.11
- 昨 收 84.52
- 总市值 0
- 52周最高 115.515
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 24.46
- 委 比 17.86%
- 总股本 --
- 历史最高 115.515
- 量 比 0.61
- 振 幅 30.90%
- 历史最低 0.23
- 每 手 1
- 风险率 27.68%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Oruka Therapeutics Says Psoriasis Drug Shows Deepening Efficacy
Oruka Therapeutics reports positive week 28 results from its Phase 2a trial for plaque psoriasis treatment ORKA-001.
09-23 21:49
Oruka Therapeutics Launches $500M Public Offering
Oruka Therapeutics, Inc. (NASDAQ:ORKA), a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis and other inflammatory and immunology indications, today
04-28 04:19
The Insider Report: The Bulls Can Thank Tech
Market Overview Stocks were up across the board last week, and weathered numero...
2025-11-03 02:31
Jefferies Initiates Coverage On Oruka Therapeutics with Buy Rating, Announces Price Target of $40
Jefferies analyst Michael Yee initiates coverage on Oruka Therapeutics (NASDAQ:ORKA) with a Buy rating and announces Price Target of $40.
2024-09-13 20:52
Wedbush Initiates Coverage On Oruka Therapeutics with Outperform Rating, Announces Price Target of $40
Wedbush analyst David Nierengarten initiates coverage on Oruka Therapeutics (NASDAQ:ORKA) with a Outperform rating and announces Price Target of $40.
2024-09-04 23:34
--Wedbush Initiates Oruka at Outperform
05:50 AM EDT, 09/04/2024 (MT Newswires) -- Price: 25.80, Change: +0.30, Percent Change: +1.18
2024-09-04 17:50
Oruka Therapeutics Completes Merger with ARCA Biopharma
10:58 AM EDT, 09/03/2024 (MT Newswires) -- Oruka Therapeutics (ORKA) said Tuesday it has completed its merger with ARCA Biopharma. The combined entity will operate as Oruka Therapeutics and start trading on the Nasdaq Global Market Tuesday under the ticker symbol "ORKA", Oruka Therapeutics said. Oru...
2024-09-03 22:58
Oruka Therapeutics Completes Merger with ARCA Biopharma, Begins Trading Under ORKA, Appoints CRISPR CEO as Chairman
Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, today announced the completion of its previously announced merger with ARCA biopharma, Inc. The ...
2024-09-03 19:06
